RegeneRx Biopharmaceuticals, Inc.
http://www.regenerx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From RegeneRx Biopharmaceuticals, Inc.
OKYO Hits Multiple Dry Eye Endpoints, Plans Move Into Phase III
OKYO’s eye drop OK-101 has hit endpoints for ocular pain, tear film breakup time and conjunctival staining in Phase II, while demonstrating a placebo-like tolerability profile.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Samsung Bioepis’ Stelara Biosimilar Shows Long-Term Similarity In Plaque Psoriasis
Hot off the press, Samsung Bioepis reports final data for its ustekinumab biosimilar SB17 in plaque psoriasis ahead of potential US market entry early next year, and gives more data on adalimumab biosimilar Hadlima to support interchangeability.
Samsung Bioepis Achieves Ophthalmology Milestone With Korean Aflibercept Approval
Samsung Bioepis has celebrated becoming the first developer to obtain approvals for both Lucentis and Eylea biosimilars, after its SB15 aflibercept candidate was approved in Korea.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice